Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
RNXT
RenovoRx, Inc.
NASDAQCM
Biotechnology
United States
$2.39
▲
+0.02 (+0.84%)
CLOSED
—
OPEN
$2.35
HIGH
$2.54
LOW
$2.28
PREV CLOSE
$2.37
VOLUME
2.08M
3.68x avg
BID / ASK
1.83 / 2.42
spr 0.590
MARKET CAP
$107.9M
DAY RANGE
$2.28
$2.54
P/E (TTM)
—
Fwd -19.9
EPS (TTM)
-0.31
DIV YIELD
—
52W HIGH
$2.59
-7.7%
52W LOW
$0.7010
+240.9%
BETA
1.12
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$2.37
-0.02
(-0.84%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
RNXT
$2.39
▲
+0.84%
Chart
Valuation
Financials
Peers
News
RNXT · K 線技術分析（即時、可互動）
basic
pro
快速分析（2–5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，一般約 2 分鐘，上游壅塞時最長約 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +92.7% YOY
1-year price chart. Started at 1.24, currently 2.39, up 92.7 percent. Range 0.73 to 2.52 over 252 data points.
2025-09-05
$1.24 → $2.39 (+92.7%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+7.0%
Terminal g
+3.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables skipped: no peer multiples or no per-share economics from Finnhub metric endpoint.
FINANCIALS
多年財務（SEC XBRL）
RISK-ON
YOY REV +2511.6% · 3 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$1.1M
-$11.2M
-$11.0M
-$11.0M
$8.1M
2024-12
$43.0K
-$8.8M
-$9.1M
-$9.1M
$8.1M
2023-12
—
-$10.2M
-$10.3M
—
$1.5M
NEWS
近期新聞（過去 14 天）
CALM
10 HEADLINES · LAST 14 DAYS
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
InvestorsHub · 2026-09-02
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
GlobeNewswire · 2026-09-02
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
GlobeNewswire · 2026-08-25
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire · 2026-08-21
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
GlobeNewswire · 2026-08-20
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
MarketBeat · 2026-08-17
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
GuruFocus.com · 2026-08-13
RenovoRx, Inc. Q2 2026 Earnings Call Summary
Moby · 2026-08-13